Breast-specific gamma imaging demonstrates better specificity and sensitivity than mammography, ultrasound, and MRI, according to several studies presented at the RSNA meeting.
Breast-specific gamma imaging demonstrates better specificity and sensitivity than mammography, ultrasound, and MRI, according to several studies presented at the RSNA meeting.
Dr. Rachel Brem, director of breast imaging and intervention at George Washington University Medical Center, and colleagues conducted a retrospective multicenter study on 26 women with biopsy-proven invasive lobular carcinoma. BSGI had the greatest sensitivity at 93%. Mammography, ultrasound, and MRI had sensitivities of 79%, 68% and 83%, respectively. BSGI also detected an additional suspicious occult lesion in 29% of women.
Dr. Leora Lanzkowsky, former medical director of the Eisenhower Medical Center in Rancho Mirage, CA, and colleagues conducted BSGI and breast MRI on patients with complex, inconclusive mammographic and/or ultrasonic findings. The researchers examined 48 patients and found 63 abnormalities.
BSGI and MRI yielded consistent results in 37 of these areas and were inconsistent in 26. MRI was inconclusive in a greater number of benign cases: 10 versus three on BSGI. The sensitivities of BSGI and MRI were 96% and 88%, respectively, with specificities of 46% and 27%.
The gamma technique images breast cancer differently from MRI, mammography, or ultrasound. Instead of approaching breast cancer in an anatomic way, BSGI examines how breast cancer functions differently from surrounding tissue. Due to an increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the pharmaceutical tracing agent injected into patients than does the normal surrounding tissue. In this way, BSGI can find occult lesions as small as 1 mm.
The radiation dose of BSGI is similar to that of mammography, according to Bob Moussa, president and CEO of Dilon Technologies, a manufacturer of a BSGI camera.
"Our BSGI imaging room is directly across from our reading room. We don't have any extra shielding. Patients can just leave and come into the general public. It's a very low dose of radiation," Brem said.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
New Interventional Radiology Research Shows Merits of Genicular Artery Embolization for Knee OA
December 3rd 2024In a cohort of over 160 patients with knee osteoarthritis (OA), including grade 4 in nearly half of the cases, genicular artery embolization led to an 87 percent improvement in the quality of life index, according to research presented at the
Siemens Healthineers Debuts New Photon-Counting CT Systems at RSNA
December 2nd 2024Debuting at the Radiological Society of North American (RSNA) conference, the new photon-counting computed tomography (PPCT) scanners Naeotom Alpha.Pro and Naeotom Alpha.Prime reportedly combine rapid scan times with high-resolution precision.